Tagged News
BlueSphere Bio Appoints Immunotherapy Pioneer Alan Korman as Chief Scientific Officer
• BlueSphere Bio has appointed Alan Korman, Ph.D., a veteran immunotherapy researcher with over 30 years of experience, as Chief Scientific Officer to advance its T cell-based therapy pipeline.
• Dr. Korman, who has served on BlueSphere's board since 2020, previously led groundbreaking immune checkpoint inhibitor research at Bristol-Myers Squibb and Medarex, directing the preclinical development of Yervoy and Opdivo.
• The appointment strengthens BlueSphere's clinical programs, which include BSB-1001 for leukemias and the upcoming TCX-102 program targeting mutant NPM-1 in AML, with an IND expected in Q2 2025.
Mestastop Solutions Seeks Approval for Phase II Trial Targeting Colorectal Cancer Metastasis
• Bengaluru-based Mestastop Solutions has applied to CDSCO for approval of a Phase II clinical trial to delay metastasis in colorectal cancer patients following surgery or chemotherapy.
• The randomized controlled, double-blind trial will involve 60 patients and is expected to run for at least two years, with patient recruitment beginning upon approval.
• Mestastop's approach focuses on preventing cancer cells from colonizing secondary sites, potentially transforming cancer treatment paradigms from damage control to disease containment.
IQVIA and Sarah Cannon Research Institute Partner to Transform Global Oncology Clinical Trials
• IQVIA and SCRI Development Innovations have formed a strategic collaboration aimed at revolutionizing oncology clinical trials through improved operations, faster data delivery, and accelerated patient access to advanced therapies.
• The partnership combines IQVIA's global reach and experience managing 20% of U.S. oncology trials with SCRI's community oncology expertise and Accelero operational model, which streamlines trial activation and data collection.
• This collaboration creates a unified, efficient model for delivering oncology trials globally, reducing vendor complexity and operational hurdles while expediting the development of innovative cancer treatments.
First European Patients Receive Accelerator-Based Boron Neutron Capture Therapy for Head and Neck Cancer
• Helsinki University Hospital and Neutron Therapeutics have treated the first European patients with accelerator-based boron neutron capture therapy (BNCT), marking the first clinical application outside of Asia.
• BNCT is a targeted radiation therapy that uses epithermal neutrons to activate boron compounds in tumor cells, delivering precise treatment in just one or two sessions while sparing healthy tissue.
• The milestone treatment is part of a ten-patient clinical trial for locally recurrent head and neck cancer using Neutron Therapeutics' nuBeam® system, with plans to expand availability throughout Europe and the United States.
Alectinib Plus Bevacizumab Shows Promising Results in First-Line Treatment of ALK-Positive NSCLC
• The ALEK-B phase 2 trial demonstrated that combining alectinib with bevacizumab significantly improved progression-free survival in ALK-positive NSCLC patients, with 97% remaining progression-free at 12 months and 64% at 36 months.
• The combination therapy showed remarkable efficacy in preventing CNS progression, with a 36-month intracranial progression-free survival rate of 87.8% and only 8.8% cumulative incidence of new brain metastases.
• Despite higher rates of adverse events compared to alectinib monotherapy, particularly proteinuria (70.7%) leading to bevacizumab discontinuation in 43.9% of patients, the treatment maintained quality of life improvements throughout the study period.
Related Clinical Trials:
Instituto Nacional de Cancerologia de Mexico
Posted 4/8/2020
Intergroupe Francophone de Cancerologie Thoracique
Posted 5/18/2022
Biodesix Presents New Data Showing Nodify Lung® Tests Improve Pulmonary Nodule Management
• New study of over 350,000 patients reveals significant gaps in lung nodule management, with approximately two-thirds receiving no clinical work-up after nodule discovery.
• Research presented at ISPOR 2025 shows concerning rates of mismanagement, with 60% of biopsies performed on benign nodules and 35% of malignant nodules receiving only follow-up CT scans.
• Real-world data from a safety-net hospital demonstrates how Biodesix's Nodify Lung® testing can guide clinical decisions through actionable results in pulmonary nodule risk stratification.
Related Clinical Trials:
NCT03289780Active, Not Recruiting
Biodesix, Inc.
Posted 4/4/2016
Avacta's pre|CISION Technology Makes Toxic Chemotherapy Safer and More Effective
• Avacta has developed a novel "masked" chemotherapy approach called pre|CISION that dramatically improves safety profiles of toxic cancer drugs while maintaining therapeutic efficacy.
• The technology works by rendering chemotherapy inactive in normal tissues and only activating the drug when it reaches the tumor microenvironment, significantly reducing systemic toxicity.
• Clinical applications of pre|CISION technology could potentially transform cancer treatment by allowing higher dosing of potent chemotherapeutics and expanding treatment options for patients who cannot tolerate conventional chemotherapy.
China Approves Xuanyuening (Bireociclib): First Dual-Indication CDK Inhibitor for Advanced Breast Cancer
• China's NMPA has approved Xuanzhu Biopharm's Bireociclib (Xuanyuening®), a novel multi-target CDK inhibitor for HR+/HER2- advanced breast cancer with dual indications.
• The drug can be used in combination with fulvestrant after endocrine therapy failure and is the only CDK4/6 inhibitor approved in China as monotherapy for heavily pretreated patients.
• Clinical trials showed impressive efficacy with median PFS of 17.5 months in combination therapy and 11 months as monotherapy, addressing specific needs of Chinese breast cancer patients.
Related Clinical Trials:
Xuanzhu Biopharmaceutical Co., Ltd.
Posted 11/16/2021
Sihuan Pharmaceutical Holdings Group Ltd.
Posted 5/22/2018
Camber Pharmaceuticals Launches Temozolomide Capsules for Brain Cancer Treatment
• Camber Pharmaceuticals has announced the launch of Temozolomide Capsules, USP, an alkylating drug used in the treatment of glioblastoma and anaplastic astrocytoma in adults.
• The medication will be available in five different strengths (5mg, 20mg, 100mg, 140mg, 180mg, and 250mg) and in various count options to support different treatment regimens.
• Temozolomide is primarily used as a concurrent treatment with radiotherapy for newly diagnosed glioblastoma patients, followed by maintenance therapy, addressing critical needs in brain cancer treatment.
Hengrui Pharmaceuticals Aims to Raise $1.27 Billion in Hong Kong IPO
• Chinese pharmaceutical giant Jiangsu Hengrui plans to raise up to $1.27 billion in its Hong Kong IPO, making it one of the city's largest offerings this year.
• The Shanghai-listed company, which focuses on oncology and metabolic diseases, has secured GIC, Invesco, and Hillhouse as cornerstone investors ahead of its expected May 23 trading debut.
• Hengrui's offering comes amid a surge in Hong Kong's IPO market, with funds raised from new listings nearly quadrupling in the first quarter compared to last year.